Search - tctmd.com

Displaying 361 - 380 of 807

Sort: Relevancy | Date

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Presentation ACC 2020

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Presenter: Frederick Raal

March 30, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

Olive Oil Consumption Linked to CVD Benefits in the US

Shelley Wood

March 09, 2020

News Daily News

One Egg a Day? No Link to Risk of CVD, Mega-Meta-analysis Says

Michael O'Riordan

March 06, 2020

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Shelley Wood

February 26, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Daily News

Free Pass? Lifestyle Slips for Patients Starting Certain Preventive Meds

Michael O'Riordan

February 06, 2020

News Daily News

Meat Consumption Linked to Small Rises in CVD, All-Cause Mortality Risks

Michael O'Riordan

February 05, 2020

News Daily News

Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol

Yael L. Maxwell

January 28, 2020

News Daily News

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Yael L. Maxwell

January 16, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Shelley Wood

January 14, 2020

News Daily News

Obesity and Aortic Stenosis: Genetic Analysis Hints at Causal Link

Yael L. Maxwell

January 13, 2020

News Daily News

Stiff Legs, Compliant Arteries: How Marathon Training Helps the Heart

Michael O'Riordan

January 07, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

Advertisement

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Olive Oil Consumption Linked to CVD Benefits in the US

One Egg a Day? No Link to Risk of CVD, Mega-Meta-analysis Says

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Free Pass? Lifestyle Slips for Patients Starting Certain Preventive Meds

Meat Consumption Linked to Small Rises in CVD, All-Cause Mortality Risks

Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Obesity and Aortic Stenosis: Genetic Analysis Hints at Causal Link

Stiff Legs, Compliant Arteries: How Marathon Training Helps the Heart

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content